Pharmion Corporation (Nasdaq: PHRM) today announced new data presented from two studies of thalidomide in combination therapy, including updated results from the pivotal MM-003 study in first-line multiple myeloma, and results from a study examining the effect of the addition of thalidomide to a post-transplant regimen. The results of these studies were presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, December 9-12, 2006).
“These data continue to validate the use of thalidomide in a first-line setting,” said Patrick J. Mahaffy, Pharmion’s president and chief executive officer. “We look forward to submitting these data as a component of our filing with the EMEA in the first quarter of 2007 for thalidomide in the treatment of newly-diagnosed myeloma.”
Statistically Significant Response Rates and Time to Progression Demonstrated in Randomized Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone for Newly Diagnosed Multiple Myeloma (Abstract 795, Oral Presentation)
S. Vincent Rajkumar, MD, of the Mayo Clinic in Rochester, Minnesota, delivered an oral presentation describing the final results of a randomized, double-blind placebo-controlled Phase 3 study evaluating the time to progression in newly-diagnosed multiple myeloma. The study compares the efficacy and safety of thalidomide plus dexamethasone versus placebo plus dexamethasone.